Eli Lilly and Company (NYSE:LLY) Shares Sold by Pennsylvania Capital Management Inc. ADV

Pennsylvania Capital Management Inc. ADV reduced its position in Eli Lilly and Company (NYSE:LLY) by 1.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,185 shares of the company’s stock after selling 61 shares during the quarter. Eli Lilly and Company comprises approximately 1.3% of Pennsylvania Capital Management Inc. ADV’s portfolio, making the stock its 15th biggest position. Pennsylvania Capital Management Inc. ADV’s holdings in Eli Lilly and Company were worth $3,456,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of LLY. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company’s stock worth $57,320,226,000 after purchasing an additional 475,530 shares during the period. Geode Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock worth $13,389,651,000 after acquiring an additional 291,875 shares during the period. GAMMA Investing LLC lifted its stake in shares of Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock worth $12,278,292,000 after acquiring an additional 14,852,076 shares during the period. Wellington Management Group LLP lifted its stake in shares of Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the period. Finally, Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter valued at about $8,407,908,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on LLY shares. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Guggenheim reissued a “buy” rating and issued a $936.00 target price on shares of Eli Lilly and Company in a report on Friday. Finally, HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,011.79.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $770.16 on Tuesday. The firm has a market cap of $729.91 billion, a price-to-earnings ratio of 62.67, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company’s 50-day moving average is $780.81 and its two-hundred day moving average is $800.36. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the company posted $2.58 earnings per share. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.